Zealand initiating new diabetes/obesity study
Zealand Pharma is now starting a phase I trial with one of the company’s candidate drugs for diabetes/obesity. Medwatch spoke to the CEO following the news that triggers a milestone payment in the range of millions.
The Danish biotech company Zealand Pharma continues to thrill investors. As expected, the company is now initiating the first clinical study with its candidate drug ZP2929 for type II diabetes and obesity.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
